Marco Valgimigli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4480299/publications.pdf

Version: 2024-02-01

667 papers	92,677 citations	1371 108 h-index	322 288 g-index
732 all docs	732 docs citations	732 times ranked	45029 citing authors

#	Article	IF	Citations
1	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2018, 39, 119-177.	2.2	7,100
2	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, 267-315.	2.2	5,890
3	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	2.2	5,583
4	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33, 2569-2619.	2.2	5,034
5	Global Burden of Cardiovascular Diseases and Risk Factors, 1990â€“2019. Journal of the American College of Cardiology, 2020, 76, 2982-3021.	2.8	4,468
6	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 2020, 41, 407-477.	2.2	4,210
7	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	2.2	4,141
8	2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal, 2013, 34, 2949-3003.	2.2	3,915
9	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. Circulation, 2011, 123, 2736-2747.	1.6	3,378
10	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2021, 42, 1289-1367.	2.2	3,048
11	Fourth universal definition of myocardial infarction (2018). European Heart Journal, 2019, 40, 237-269.	2.2	2,687
12	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2018, 39, 213-260.	2.2	2,246
13	2014 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2014, 46, 517-592.	1.4	2,164
14	Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. New England Journal of Medicine, 2007, 356, 1030-1039.	27.0	1,182
15	Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet, The, 2015, 385, 2465-2476.	13.7	1,043
16	Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet, The, 2017, 389, 1025-1034.	13.7	840
17	Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. New England Journal of Medicine, 2012, 366, 20-33.	27.0	701
18	Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting. Circulation, 2012, 125, 2015-2026.	1.6	640

#	Article	IF	Citations
19	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet, The, 2018, 392, 940-949.	13.7	555
20	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. European Heart Journal, 2014, 35, 3155-3179.	2.2	490
21	Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet, The, 2019, 394, 1335-1343.	13.7	465
22	Diagnostic Performance of Multislice Spiral Computed Tomography of Coronary Arteries as Compared With Conventional Invasive Coronary Angiography. Journal of the American College of Cardiology, 2006, 48, 1896-1910.	2.8	439
23	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2019, 140, 240-261.	1.6	428
24	Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet, The, 2012, 380, 1482-1490.	13.7	412
25	Long-Term Safety of Drug-Eluting andÂBare-Metal Stents. Journal of the American College of Cardiology, 2015, 65, 2496-2507.	2.8	396
26	Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease. JACC: Cardiovascular Interventions, 2016, 9, 1419-1434.	2.9	385
27	Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 58, 1945-1954.	2.8	383
28	Updated Expert Consensus Statement on Platelet Function and Genetic Testing forÂGuiding P2Y12 Receptor Inhibitor Treatment in Percutaneous CoronaryÂIntervention. JACC: Cardiovascular Interventions, 2019, 12, 1521-1537.	2.9	366
29	In Vivo Intravascular Ultrasound-Derived Thin-Cap Fibroatheroma Detection Using Ultrasound Radiofrequency Data Analysis. Journal of the American College of Cardiology, 2005, 46, 2038-2042.	2.8	364
30	A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. New England Journal of Medicine, 2020, 382, 120-129.	27.0	362
31	CD34+and Endothelial Progenitor Cells in Patients With Various Degrees of Congestive Heart Failure. Circulation, 2004, 110, 1209-1212.	1.6	360
32	Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. European Heart Journal, 2007, 28, 2706-2713.	2.2	337
33	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European Heart Journal, 2019, 40, 2632-2653.	2.2	335
34	Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. New England Journal of Medicine, 2015, 373, 997-1009.	27.0	334
35	Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. Journal of the American College of Cardiology, 2016, 68, 1851-1864.	2.8	319
36	Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients Treated With Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 57, 2474-2483.	2.8	315

#	Article	IF	Citations
37	Short- and Long-Term Clinical Outcome After Drug-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease. Circulation, 2005, 111, 1383-1389.	1.6	305
38	Bleeding and stent thrombosis on P2Y₁₂-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. European Heart Journal, 2015, 36, 1762-1771.	2.2	297
39	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. European Heart Journal, 2016, 37, ehv443.	2.2	293
40	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptorâ€“Inhibiting Therapies. Circulation, 2017, 136, 1955-1975.	1.6	293
41	Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ, The, 2014, 348, g3859-g3859.	6.0	291
42	Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2005, 293, 2109.	7.4	290
43	Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ, The, 2015, 350, h1618-h1618.	6.0	279
44	ACC/AHA Versus ESC Guidelines on DualÂAntiplatelet Therapy. Journal of the American College of Cardiology, 2018, 72, 2915-2931.	2.8	273
45	Cyphering the Complexity of Coronary Artery Disease Using the Syntax Score to Predict Clinical Outcome in Patients With Three-Vessel Lumen Obstruction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2007, 99, 1072-1081.	1.6	269
46	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2018, 53, 34-78.	1.4	261
47	2014 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention, 2015, 10, 1024-1094.	3.2	251
48	Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates. Journal of the American College of Cardiology, 2015, 65, 805-815.	2.8	248
49	Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. New England Journal of Medicine, 2021, 385, 1643-1655.	27.0	247
50	European expert consensus on rotational atherectomy. EuroIntervention, 2015, 11, 30-36.	3.2	247
51	Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction<subtitle>The MULTISTRATEGY Randomized Trial</subtitle>. JAMA - Journal of the American Medical Association, 2008, 299, 1788.	7.4	245
52	European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. European Heart Journal, 2019, 40, 3182-3195.	2.2	240
53	Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Nonaccess Site Bleeding in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 191-197.	2.9	229
54	Long-Term Outcomes After Stenting of Bifurcation Lesions With the â€œCrushâ€•Technique. Journal of the American College of Cardiology, 2006, 47, 1949-1958.	2.8	228

#	Article	IF	Citations
55	Dual Antiplatelet Therapy Duration BasedÂon Ischemic and Bleeding Risks After CoronaryÂStenting. Journal of the American College of Cardiology, 2019, 73, 741-754.	2.8	218
56	Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II). Circulation, 2011, 124, 1260-1269.	1.6	217
57	Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. Heart, 2014, 100, 1158-1164.	2.9	216
58	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet, The, 2018, 392, 835-848.	13.7	215
59	Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. European Heart Journal, 2005, 26, 1838-1845.	2.2	214
60	Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention. Circulation, 2009, 119, 3215-3222.	1.6	213
61	A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions: The AVIO trial. American Heart Journal, 2013, 165, 65-72.	2.7	212
62	Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. European Heart Journal, 2019, 40, 3757-3767.	2.2	211
63	Clinical Outcomes With Drug-Eluting and Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2013, 62, 496-504.	2.8	210
64	2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm So. Europace, 2019, 21, 192-193.	1.7	209
65	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 618-628.	11.4	207
66	The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population. Journal of the American College of Cardiology, 2005, 45, 1135-1141.	2.8	204
67	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Revista Espanola De Cardiologia (English Ed), 2017, 70, 1082.	0.6	189
68	Tumor Necrosis Factor-Î± Receptor 1 Is a Major Predictor of Mortality and New-Onset Heart Failure in Patients With Acute Myocardial Infarction. Circulation, 2005, 111, 863-870.	1.6	185
69	Favorable Long-Term Outcome After Drug-Eluting Stent Implantation in Nonbifurcation Lesions That Involve Unprotected Left Main Coronary Artery. Circulation, 2007, 116, 158-162.	1.6	182
70	Distal Left Main Coronary Disease Is a Major Predictor of Outcome in Patients Undergoing Percutaneous Intervention in the Drug-Eluting Stent Era. Journal of the American College of Cardiology, 2006, 47, 1530-1537.	2.8	181
71	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nature Reviews Cardiology, 2018, 15, 480-496.	13.7	180
72	Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. Lancet, The, 2016, 387, 357-366.	13.7	174

#	Article	IF	Citations
73	A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease. American Heart Journal, 2008, 155, 274-283.	2.7	170
74	Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet, The, 2019, 393, 2503-2510.	13.7	166
75	Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. European Heart Journal, 2017, 38, ehw525.	2.2	164
76	Short- Versus Long-Term DualÂAntiplateletÂTherapy After Drug-ElutingÂStent Implantation. Journal of the American College of Cardiology, 2015, 65, 1092-1102.	2.8	163
77	Prasugrel Versus Tirofiban Bolus With or Without Short Post-Bolus Infusion With or Without Concomitant Prasugrel Administration in Patients With Myocardial Infarction Undergoing Coronary Stenting. JACC: Cardiovascular Interventions, 2012, 5, 268-277.	2.9	162
78	Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2008, 51, 2212-2219.	2.8	160
79	Multislice Spiral Computed Tomography for the Evaluation of Stent Patency After Left Main Coronary Artery Stenting. Circulation, 2006, 114, 645-653.	1.6	155
80	The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty. Journal of the American College of Cardiology, 2004, 44, 14-19.	2.8	151
81	P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ, The, 2021, 373, n1332.	6.0	144
82	Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. New England Journal of Medicine, 2021, 385, 2150-2160.	27.0	144
83	From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells. European Heart Journal, 2008, 30, 890-899.	2.2	143
84	Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: A long-term prospective study. Hepatology, 1999, 30, 58-64.	7.3	141
85	Value of Platelet Reactivity in Predicting Response to Treatment and Clinical Outcome in Patients Undergoing Primary Coronary Intervention. Journal of the American College of Cardiology, 2006, 48, 2178-2185.	2.8	140
86	Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. European Heart Journal, 2012, 33, 3098-3104.	2.2	138
87	Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11â€‰473 patients. European Heart Journal, 2017, 38, ehw627.	2.2	138
88	Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet, The, 2019, 394, 1243-1253.	13.7	138
89	Stem Cell Mobilization by Granulocyte Colony-Stimulating Factor for Myocardial Recovery After Acute Myocardial Infarction. Journal of the American College of Cardiology, 2008, 51, 1429-1437.	2.8	136
90	Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. BMJ: British Medical Journal, 2006, 332, 202-209.	2.3	135

#	Article	IF	Citations
91	Is Bare-Metal Stent Implantation StillÂJustifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?. JACC: Cardiovascular Interventions, 2016, 9, 426-436.	2.9	135
92	Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. European Heart Journal, 2012, 33, 977-987.	2.2	134
93	Prediction of 1-Year Clinical Outcomes Using the SYNTAX Score in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 66-75.	2.9	132
94	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. Journal of the American College of Cardiology, 2017, 69, 2592-2603.	2.8	132
95	Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. EuroIntervention, 2020, 16, 371-379.	3.2	132
96	Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. International Journal of Cardiology, 2011, 150, 325-331.	1.7	129
97	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet, The, 2013, 382, 1879-1888.	13.7	127
98	Two-Year Outcomes After First- or Second-Generation Drug-Eluting or Bare-Metal Stent Implantation in All-Comer Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 20-28.	2.9	124
99	Transradial Coronary Catheterization and Intervention Across the Whole Spectrum of Allen Test Results. Journal of the American College of Cardiology, 2014, 63, 1833-1841.	2.8	123
100	Excimer Laser LEsion Modification to Expand Non-dilatable sTents: The ELLEMENT Registry. Cardiovascular Revascularization Medicine, 2014, 15, 8-12.	0.8	122
101	Drug-Eluting Stent for Left Main Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 718-727.	2.9	121
102	Long-Term Clinical Outcome Based on Aspirin and Clopidogrel Responsiveness Status After Elective Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2010, 56, 1447-1455.	2.8	118
103	Coronary artery remodelling is related to plaque composition. Heart, 2005, 92, 388-391.	2.9	114
104	Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. International Journal of Cardiology, 2013, 167, 2140-2148.	1.7	113
105	Noninvasive Detection of Subclinical Coronary Atherosclerosis Coupled With Assessment of Changes in Plaque Characteristics Using Novel Invasive Imaging Modalities. Journal of the American College of Cardiology, 2006, 47, 1134-1142.	2.8	112
106	Best Practices for the Prevention of Radial Artery Occlusion After Transradial Diagnostic Angiography and Intervention. JACC: Cardiovascular Interventions, 2019, 12, 2235-2246.	2.9	111
107	Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Interventionâ€â€Conflicts of interest: Dr. Angiolillo is a consultant and on the speakerâ€™s bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami, Florida, and received lecture fees from Bristol Myers Squibb. Dr. Montalescot has been a consultant for and/or received research grants from Sa. American Journal of Cardiology, 2007, 100, 1199-1206.	1.6	110
108	Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet, The, 2016, 387, 349-356.	13.7	109

#	Article	IF	Citations
109	Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. Journal of the American College of Cardiology, 2017, 69, 2011-2022.	2.8	109
110	Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). European Heart Journal, 2013, 34, 909-919.	2.2	108
111	Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs. Thrombosis and Haemostasis, 2019, 119, 149-162.	3.4	107
112	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace, 2014, 16, 1655-1673.	1.7	105
113	Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. European Heart Journal, 2010, 31, 35-49.	2.2	103
114	Transradial Versus Transfemoral Intervention for Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2012, 5, 23-35.	2.9	101
115	Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. Journal of the American College of Cardiology, 2019, 74, 2223-2234.	2.8	101
116	Left ventricular unloading and concomitant total cardiac output increase by the use of percutaneous impella recover LP 2.5 assist device during high-risk coronary intervention. Catheterization and Cardiovascular Interventions, 2005, 65, 263-267.	1.7	100
117	Sirolimus-Eluting Versus Paclitaxel-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2006, 47, 507-514.	2.8	100
118	Open-Label, Randomized, Placebo-Controlled Evaluation of Intracoronary Adenosine or Nitroprusside After Thrombus Aspiration During Primary Percutaneous Coronary Intervention for the Prevention of Microvascular Obstruction in Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2013, 6, 580-589.	2.9	100
119	Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry. European Heart Journal, 2008, 29, 2108-2115.	2.2	99
120	Frequency, Timing, and Impact of Access-Site and Nonâ€“Access-Site BleedingÂon Mortality Among PatientsÂUndergoing Transcatheter AorticÂValveÂReplacement. JACC: Cardiovascular Interventions, 2017, 10, 1436-1446.	2.9	99
121	Oxidative Stress EPR Measurement in Human Liver by Radical-probe Technique. Correlation with Etiology, Histology and Cell Proliferation. Free Radical Research, 2002, 36, 939-948.	3.3	97
122	Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes. JAMA Cardiology, 2019, 4, 1092.	6.1	97
123	Comparison of Newer-Generation Drug-Eluting With Bare-Metal Stents inÂPatients With Acute ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2014, 7, 55-63.	2.9	96
124	The Significance of Drugâ€“Drug and Drugâ€“Food Interactions of Oral Anticoagulation. Arrhythmia and Electrophysiology Review, 2018, 7, 55.	2.4	96
125	Comparison of early outcome of percutaneous coronary intervention for unprotected left main coronary artery disease in the drug-eluting stent era with versus without intravascular ultrasonic guidance. American Journal of Cardiology, 2005, 95, 644-647.	1.6	95
126	Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. American Heart Journal, 2017, 184, 81-87.	2.7	95

#	Article	IF	Citations
127	Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. European Heart Journal, 2019, 40, 2595-2604.	2.2	93
128	Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. EuroIntervention, 2016, 12, 1239-1245.	3.2	92
129	Role for Substance Pâ€“Based Nociceptive Signaling in Progenitor Cell Activation and Angiogenesis During Ischemia in Mice and in Human Subjects. Circulation, 2012, 125, 1774-1786.	1.6	90
130	Angiographic and Optical Coherence Tomography Insights Into Bioresorbable Scaffold Thrombosis. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	90
131	Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. European Heart Journal, 2021, 42, 308-319.	2.2	90
132	Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. International Journal of Cardiology, 2009, 133, 213-222.	1.7	89
133	Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. European Heart Journal, 2020, 41, 3743-3749.	2.2	89
134	Coronary plaque composition of nonculprit lesions, assessed by in vivo intracoronary ultrasound radio frequency data analysis, is related to clinical presentation. American Heart Journal, 2006, 151, 1020-1024.	2.7	87
135	Current use of intracoronary imaging in interventional practice â€“ Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey. EuroIntervention, 2018, 14, e475-e484.	3.2	87
136	Prognostic Value of Right Ventricular Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Imaging, 2019, 12, 577-587.	5.3	85
137	Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism?. Journal of the American College of Cardiology, 2007, 50, 1132-1137.	2.8	82
138	Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. BMJ, The, 2014, 349, g6427-g6427.	6.0	82
139	A Multidisciplinary Approach on theÂPerioperative Antithrombotic ManagementÂof Patients With CoronaryÂStents Undergoing Surgery. JACC: Cardiovascular Interventions, 2018, 11, 417-434.	2.9	81
140	The EXAMINATION Trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.9	80
141	Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segmentâ€“Elevation Myocardial Infarction and Multivessel Disease. Circulation: Cardiovascular Interventions, 2018, 11, e006023.	3.9	80
142	Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. American Heart Journal, 2018, 196, 105-112.	2.7	80
143	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation, 2020, 141, 781-783.	1.6	80
144	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. European Heart Journal, 2021, 42, 4638-4651.	2.2	80

#	Article	IF	Citations
145	Two-Year Clinical Follow-Up After Sirolimus-Eluting Versus Bare-Metal Stent Implantation Assisted by Systematic Glycoprotein IIb/IIIa Inhibitor Infusion in Patients With Myocardial Infarction. Journal of the American College of Cardiology, 2007, 50, 138-145.	2.8	78
146	Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress. Archives of Biochemistry and Biophysics, 2003, 420, 255-261.	3.0	76
147	Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. European Heart Journal, 2015, 36, 1242-1251.	2.2	76
148	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for Ostial/Mid-Shaft Lesions Versus Distal Bifurcation Lesions in Unprotected LeftÂMain Coronary Artery. JACC: Cardiovascular Interventions, 2013, 6, 1242-1249.	2.9	75
149	â€œFull metal jacketâ€•(stented length â‰¥64 mm) using drug-eluting stents for de novo coronary artery lesions. American Heart Journal, 2005, 150, 994-999.	2.7	74
150	Global characterization of coronary plaque rupture phenotype using three-vessel intravascular ultrasound radiofrequency data analysis. European Heart Journal, 2006, 27, 1921-1927.	2.2	71
151	Bleeding avoidance strategies in percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 117-132.	13.7	71
152	A Patient-Level Pooled Analysis Assessing the Impact of the SYNTAX (Synergy Between Percutaneous) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Patients Enrolled in Contemporary Coronary Stent Trials. JACC: Cardiovascular Interventions, 2011, 4, 645-653.	2.9	70
153	A Critical Appraisal of Aspirin in Secondary Prevention. Circulation, 2016, 134, 1881-1906.	1.6	70
154	Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute CoronaryÂSyndromes. Journal of the American College of Cardiology, 2021, 77, 375-388.	2.8	70
155	Zotarolimus- Versus Everolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2013, 62, 2075-2082.	2.8	69
156	Comprehensive Meta-Analysis of Safety and Efficacy of Bivalirudin Versus Heparin With or Without Routine Glycoprotein IIb/IIIa Inhibitors in Patients With AcuteÂCoronary Syndrome. JACC: Cardiovascular Interventions, 2015, 8, 201-213.	2.9	69
157	Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 203-210.	3.0	69
158	Distance from the ostium as an independent determinant of coronary plaque composition in vivo: an intravascular ultrasound study based radiofrequency data analysis in humans. European Heart Journal, 2006, 27, 655-663.	2.2	68
159	Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease. JAMA Cardiology, 2016, 1, 795.	6.1	68
160	A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With DiabetesÂMellitus. JACC: Cardiovascular Interventions, 2016, 9, 42-50.	2.9	68
161	Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segmentâ€“Elevation Myocardial Infarction. Circulation, 2020, 142, 441-454.	1.6	67
162	Serum From Patients With Acute Coronary Syndromes Displays a Proapoptotic Effect on Human Endothelial Cells. Circulation, 2003, 107, 264-270.	1.6	66

#	Article	IF	Citations
163	Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention. American Heart Journal, 2010, 160, 804-811.	2.7	66
164	Plaque Composition and its Relationship With Acknowledged Shear Stress Patterns in Coronary Arteries. Journal of the American College of Cardiology, 2006, 47, 884-885.	2.8	65
165	Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). European Heart Journal, 2019, 40, 2070-2085.	2.2	64
166	Percutaneous Coronary Interventions forÂthe Treatment of Stenoses in Small Coronary Arteries. JACC: Cardiovascular Interventions, 2016, 9, 1324-1334.	2.9	63
167	Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillationâ€"Rationale and design of the ENVISAGE-TAVI AF trial. American Heart Journal, 2018, 205, 63-69.	2.7	62
168	Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, nonâ€"ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction. American Heart Journal, 2016, 175, 56-65.	2.7	61
169	Radiation Exposure and Vascular AccessÂinÂAcute Coronary Syndromes. Journal of the American College of Cardiology, 2017, 69, 2530-2537.	2.8	61
170	Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial. Circulation, 2022, 145, 724-738.	1.6	61
171	Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement With Supra-Annular and Intra-Annular Prostheses. JACC: Cardiovascular Interventions, 2019, 12, 2173-2182.	2.9	60
172	Reproducibility of intravascular ultrasound radiofrequency data analysis: implications for the design of longitudinal studies. International Journal of Cardiovascular Imaging, 2006, 22, 621-631.	1.5	59
173	Incremental Value of the CRUSADE, ACUITY, and HASâ€BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy. Journal of the American Heart Association, 2015, 4, .	3.7	59
174	The Rotterdam Radial Access Research. Circulation: Cardiovascular Interventions, 2016, 9, e003129.	3.9	59
175	Thrombo-embolic prevention after transcatheter aortic valve implantation. European Heart Journal, 2017, 38, 3341-3350.	2.2	59
176	Short- Versus Long-Term Duration of Dual Antiplatelet Therapy in Patients Treated for In-Stent Restenosis. Journal of the American College of Cardiology, 2014, 63, 506-512.	2.8	58
177	The Impact of Left Ventricular Diastolic Dysfunction on Clinical Outcomes After TranscatheterÂAortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 593-601.	2.9	58
178	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. Journal of the American College of Cardiology, 2021, 78, 421-433.	2.8	58
179	Single-vessel versus bifurcation stenting for the treatment of distal left main coronary artery disease in the drug-eluting stenting era. Clinical and angiographic insights into the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registries. American Heart Journal, 2006, 152, 896-902.	2.7	57
180	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Revista Espanola De Cardiologia (English Ed), 2015, 68, 1125.	0.6	57

#	Article	IF	Citations
181	Measurement of oxidative stress in human liver by EPR spin-probe technique. Free Radical Research, 2000, 33, 167-178.	3.3	56
182	Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention. Annals of Internal Medicine, 2017, 167, 17.	3.9	56
183	3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. JACC: Cardiovascular Interventions, 2021, 14, 1870-1883.	2.9	56
184	Prediction of 1-Year Mortality in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2013, 6, 737-745.	2.9	54
185	Rates and predictors of hospital readmission after transcatheter aortic valve implantation. European Heart Journal, 2017, 38, 2211-2217.	2.2	54
186	Short-Term Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Elderly Patients. JACC: Cardiovascular Interventions, 2018, 11, 435-443.	2.9	54
187	Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. Europace, 2020, 22, 33-46.	1.7	54
188	Tissue Factor and Coagulation Factor VII Levels During Acute Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2800-2806.	2.4	53
189	Poor response to clopidogrel: current and future options for its management. Journal of Thrombosis and Thrombolysis, 2010, 30, 319-331.	2.1	53
190	Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial. American Heart Journal, 2016, 174, 95-102.	2.7	53
191	Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. American Heart Journal, 2019, 209, 97-105.	2.7	53
192	Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology, 2020, 75, 2588-2597.	2.8	53
193	Stent-related defects in patients presenting with stent thrombosis: differences at optical coherence tomography between subacute and late/very late thrombosis in the Mechanism Of Stent Thrombosis (MOST) study. EuroIntervention, 2013, 9, 936-944.	3.2	53
194	Comparison of Short- (One Month) and Long- (Twelve Months) Term Outcomes of Sirolimus- Versus Paclitaxel-Eluting Stents in 293 Consecutive Patients With Diabetes Mellitus (from the RESEARCH and) Tj ETQq0 0 1 rgBT /Overlock 10 T	1.6	52
195	Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. European Heart Journal, 2017, 38, 1069-1080.	2.2	52
196	Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation. JAMA Cardiology, 2021, 6, 410.	6.1	52
197	Plaque Composition in the Left Main Stem Mimics the Distal But Not the Proximal Tract of the Left Coronary Artery. Journal of the American College of Cardiology, 2007, 49, 23-31.	2.8	51
198	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 674-684.	2.9	51

#	Article	IF	Citations
199	Predicting 3-Year Mortality After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 464-470.	2.9	50
200	Serum Xanthine Oxidase in Human Liver Disease. American Journal of Gastroenterology, 2001, 96, 1194-1199.	0.4	49
201	Long-Term Clinical Results Following Stenting of the Left Main Stem. JACC: Cardiovascular Interventions, 2010, 3, 584-594.	2.9	49
202	Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. European Heart Journal, 2014, 35, 2524-2529.	2.2	49
203	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention. JAMA Cardiology, 2020, 5, 21.	6.1	49
204	Genetic determinants of on-clopidogrel high platelet reactivity. Platelets, 2011, 22, 399-407.	2.3	48
205	Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ, The, 2016, 355, i5483.	6.0	48
206	Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. EuroIntervention, 2015, 11, 68-74.	3.2	48
207	Design and rationale for the Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program. American Heart Journal, 2014, 168, 838-845.e6.	2.7	47
208	Safety of optical coherence tomography in daily practice: a comparison with intravascular ultrasound. European Heart Journal Cardiovascular Imaging, 2017, 18, jew037.	1.2	47
209	Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management. JACC: Cardiovascular Interventions, 2018, 11, 36-50.	2.9	47
210	Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction. Journal of the American College of Cardiology, 2004, 43, 2000-2008.	2.8	46
211	Longâ€term outcome in patients with ST segment elevation myocardial infarction and multivessel disease treated with culpritâ€only, immediate, or staged multivessel percutaneous revascularization strategies: Insights from the REAL registry. Catheterization and Cardiovascular Interventions, 2014, 84, 912-922.	1.7	46
212	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 386-386.	1.0	46
213	Device-Related Thrombus After Left Atrial Appendage Closure: Data on Thrombus Characteristics, Treatment Strategies, and Clinical Outcomes From the EUROC-DRT-Registry. Circulation: Cardiovascular Interventions, 2021, 14, e010195.	3.9	46
214	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Ostial/Midshaft Lesions in Unprotected Left Main Coronary Artery From the DELTA Registry. JACC: Cardiovascular Interventions, 2014, 7, 354-361.	2.9	45
215	Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition. EuroIntervention, 2021, 17, e898-e909.	3.2	45
216	Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. BMJ, The, 2016, 354, i4935.	6.0	43

#	Article	IF	Citations
217	Radial vs femoral access for the prevention of acute kidney injury (AKI) after coronary angiography or intervention: A systematic review and metaâ€analysis. Catheterization and Cardiovascular Interventions, 2018, 92, E518-E526.	1.7	43
218	Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function andÂOther Vascular Biomarkers. JACC: Cardiovascular Interventions, 2018, 11, 1576-1586.	2.9	43
219	Scientific Foundation and Possible Implications for Practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX (MATRIX) Trial. Journal of Cardiovascular Translational Research, 2014, 7, 101-111.	2.4	42
220	Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: Insights from a systematic overview of randomized trials in light of the drug-eluting stent era. American Heart Journal, 2006, 151, 682-689.	2.7	41
221	Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. Circulation, 2021, 144, 1196-1211.	1.6	41
222	Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. EuroIntervention, 2011, 7, 977-984.	3.2	41
223	Evaluation of Microvascular Injury in Revascularized Patients With ST-Segmentâ€“Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel. Circulation, 2019, 139, 636-646.	1.6	40
224	Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: A meta-analysis of randomized trials. International Journal of Cardiology, 2013, 168, 2579-2587.	1.7	39
225	Pretreatment With P2Y ₁₂ Inhibitors in Nonâ€“ST-Segmentâ€“Elevation Acute Coronary Syndrome Is Clinically Justified. Circulation, 2014, 130, 1891-1903.	1.6	39
226	Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. European Journal of Cardio-thoracic Surgery, 2017, 52, 206-217.	1.4	39
227	PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 28-38.	3.0	39
228	Duration of Dual Antiplatelet Therapy forÂPatients at High Bleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 2021, 78, 2060-2072.	2.8	39
229	The 5-Year Clinical Outcomes After a Randomized Comparison of Sirolimus-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2009, 54, 1900-1901.	2.8	38
230	Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice. Circulation: Cardiovascular Interventions, 2018, 11, e006132.	3.9	38
231	Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. European Heart Journal, 2022, 43, 3100-3114.	2.2	38
232	Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. Hepatology, 2000, 31, 349-357.	7.3	37
233	One year clinical follow up of paclitaxel eluting stents for acute myocardial infarction compared with sirolimus eluting stents. Heart, 2005, 91, 1176-1180.	2.9	37
234	Effect of perindopril on coronary remodelling: insights from a multicentre, randomized study. European Heart Journal, 2007, 28, 2326-2331.	2.2	37

#	Article	IF	Citations
235	Acute kidney injury after percutaneous coronary intervention: Rationale of the <scp>AKIâ€MATRIX</scp> (acute kidney injuryâ€minimizing adverse hemorrhagic events by TRansradial access site and systemic) Tj ETQq1 1 0.784314 rgBT /Over 2015, 86, 950-957.	1.7	37
236	Impact of vascular access on acute kidney injury after percutaneous coronary intervention. Cardiovascular Revascularization Medicine, 2016, 17, 333-338.	0.8	37
237	State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation â€“ past, present and future perspectives. EuroIntervention, 2017, 13, 717-733.	3.2	37
238	Rationale and methods of the integrated biomarker and imaging study (IBIS): combining invasive and non-invasive imaging with biomarkers to detect subclinical atherosclerosis and assess coronary lesion biology. International Journal of Cardiovascular Imaging, 2005, 21, 425-441.	1.5	36
239	Assisted circulation using the TandemHeartÂ® during very highâ€risk PCI of the unprotected left main coronary artery in patients declined for CABG. Catheterization and Cardiovascular Interventions, 2009, 74, 302-310.	1.7	36
240	Early versus newer generation devices for transcatheter aortic valve implantation in routine clinical practice: a propensity score matched analysis. Open Heart, 2018, 5, e000695.	2.3	36
241	Validation of High-Risk Features for Stent-Related Ischemic Events as Endorsed by the 2017 DAPT Guidelines. JACC: Cardiovascular Interventions, 2019, 12, 820-830.	2.9	36
242	Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. Atherosclerosis, 2020, 295, 45-53.	0.8	36
243	Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea. Circulation, 2018, 138, 646-648.	1.6	35
244	Trial Design Principles for Patients at HighÂBleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 2020, 76, 1468-1483.	2.8	35
245	Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. EuroIntervention, 2016, 11, e1222-e1230.	3.2	35
246	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. Circulation, 2021, 144, 1323-1343.	1.6	35
247	Intramyocardial injection of skeletal myoblasts: long-term follow-up with pressureâ€“volume loops. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, S94-S100.	3.3	34
248	Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. Clinical Research in Cardiology, 2010, 99, 345-357.	3.3	34
249	Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?. American Heart Journal, 2014, 168, 611-621.	2.7	34
250	Cardiovascular events and re-stenosis following administration of G-CSF in acute myocardial infarction: systematic review and meta-analysis. Heart, 2008, 94, 610-616.	2.9	33
251	Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI. JACC: Cardiovascular Interventions, 2021, 14, 639-648.	2.9	33
252	Percutaneous therapy of bifurcation lesions with drugâ€eluting stent implantation: the Culotte technique revisited. International Journal of Cardiovascular Interventions, 2005, 7, 36-40.	0.5	32

#	Article	IF	Citations
253	Factor XIIIA-V34L and Factor XIIIB-H95R Gene Variants: Effects on Survival in Myocardial Infarction Patients. Molecular Medicine, 2007, 13, 112-120.	4.4	32
254	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 712 Td (No Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. American Journal of Cardiology, 2015, 116, 845-852.	1.6	32
255	Correlates and Impact of Coronary ArteryÂCalcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 1890-1901.	2.9	32
256	Transfemoral Approach for CoronaryÂAngiography and Intervention. JACC: Cardiovascular Interventions, 2017, 10, 2269-2279.	2.9	32
257	Bivalirudin or Heparin in Patients Undergoing Invasive Management of AcuteÂCoronaryÂSyndromes. Journal of the American College of Cardiology, 2018, 71, 1231-1242.	2.8	32
258	Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention?. European Heart Journal, 2019, 40, 216-217.	2.2	32
259	Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. Clinical Pharmacology and Therapeutics, 2020, 108, 1067-1077.	4.7	32
260	European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions. European Heart Journal, 2021, 42, 1545-1553.	2.2	32
261	Migratory activity of circulating progenitor cells and serum SDF-1Î± predict adverse events in patients with myocardial infarction. Cardiovascular Research, 2013, 100, 192-200.	3.8	31
262	Randomized comparison between 3-month Cre8 DES vs. 1-month Vision/Multilink8 BMS neointimal coverage assessed by OCT evaluation: The DEMONSTRATE study. International Journal of Cardiology, 2014, 176, 904-909.	1.7	31
263	Effect of Chronic Kidney Disease in WomenÂUndergoing Percutaneous CoronaryÂIntervention With Drug-ElutingÂStents. JACC: Cardiovascular Interventions, 2016, 9, 28-38.	2.9	31
264	Effect of Pre-Hospital Ticagrelor During the FirstÂ24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2016, 9, 646-656.	2.9	31
265	Current Use of Intracoronary Imaging in Interventional Practiceã€€â€• Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey â€•. Circulation Journal, 2018, 82, 1360-1368.	1.6	31
266	Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis. EuroIntervention, 2021, 17, 550-560.	3.2	31
267	Impact of Stable Versus Unstable Coronary Artery Disease on 1-Year Outcome in Elective Patients Undergoing Multivessel Revascularization With Sirolimus-Eluting Stents. Journal of the American College of Cardiology, 2007, 49, 431-441.	2.8	30
268	Optimization in Stent Implantation by Manual Thrombus Aspiration in ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2014, 7, 294-300.	3.9	30
269	Incidence, prognostic impact, and optimal definition of contrastâ€induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the allâ€comer <scp>PRODIGY</scp> trial. Catheterization and Cardiovascular Interventions, 2015, 86, E19-27.	1.7	30
270	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 829-844.	13.7	30

#	Article	IF	Citations
271	Relationship between paraoxonase Q192R gene polymorphism and onâ€clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention. Journal of Thrombosis and Haemostasis, 2011, 9, 2106-2108.	3.8	29
272	Persistent Coronary No Flow After Wire Insertion Is an Early and Readily Available Mortality Risk Factor Despite Successful Mechanical Intervention in Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2011, 4, 51-62.	2.9	29
273	Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY). International Journal of Cardiology, 2013, 165, 134-141.	1.7	29
274	Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus?. European Heart Journal, 2015, 36, 1219-1222.	2.2	29
275	EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). European Heart Journal, 2016, 37, 152-160.	2.2	29
276	The impact of functional vs degenerative mitral regurgitation on clinical outcomes among patients undergoing transcatheter aortic valve implantation. American Heart Journal, 2017, 184, 71-80.	2.7	29
277	Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Revista Espanola De Cardiologia (English Ed), 2018, 71, 42.	0.6	29
278	A tool for predicting the outcome of reperfusion in ST-elevation myocardial infarction using age, thrombotic burden and index of microcirculatory resistance (ATI score). EuroIntervention, 2016, 12, 1223-1230.	3.2	29
279	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. EuroIntervention, 2015, 10, 1095-1108.	3.2	29
280	Stress and tissue Doppler echocardiographic evidence of effectiveness of myoblast transplantation in patients with ischaemic heart failure. European Journal of Heart Failure, 2006, 8, 641-648.	7.1	28
281	Early Angio-Guided Complete Revascularization versus Culprit Vessel PCI Followed by Ischemia-Guided Staged PCI in STEMI Patients with Multivessel Disease. Journal of Interventional Cardiology, 2011, 24, 535-541.	1.2	28
282	Effects of Body Mass Index on ClinicalÂOutcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2018, 11, 68-76.	2.9	28
283	Does isolated mitral annular calcification in the absence of mitral valve disease affect clinical outcomes after transcatheter aortic valve replacement?. European Heart Journal Cardiovascular Imaging, 2020, 21, 522-532.	1.2	28
284	Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk. Circulation, 2020, 141, 891-901.	1.6	28
285	Patient-tailored antithrombotic therapy following percutaneous coronary intervention. European Heart Journal, 2021, 42, 1038-1046.	2.2	28
286	Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. Thrombosis and Haemostasis, 2014, 112, 883-891.	3.4	27
287	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. JACC: Cardiovascular Interventions, 2021, 14, 444-456.	2.9	27
288	Rapid exchange ultra-thin microcatheter using fibre-optic sensing technology for measurement of intracoronary fractional flow reserve. EuroIntervention, 2015, 11, 428-432.	3.2	27

#	Article	IF	Citations
289	Is Late Luminal Loss an Accurate Predictor of the Clinical Effectiveness of Drug-Eluting Stents in the Coronary Arteries?. American Journal of Cardiology, 2006, 97, 603-605.	1.6	26
290	Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: Analysis from the SPIRIT FIRST trial. Catheterization and Cardiovascular Interventions, 2006, 67, 188-197.	1.7	26
291	2014 ESC/EACTS Guidelines on Myocardial Revascularization. Revista Espanola De Cardiologia (English) Tj ETQq1 1 0.784314 rgBT /O	0.6	26
292	Validity of SYNTAX score II for risk stratification of percutaneous coronary interventions: A patient-level pooled analysis of 5433 patients enrolled in contemporary coronary stent trials. International Journal of Cardiology, 2015, 187, 111-115.	1.7	26
293	Impact of greater than 12-month dual antiplatelet therapy duration on mortality: Drug-specific or a class-effect? A meta-analysis. International Journal of Cardiology, 2015, 201, 179-181.	1.7	26
294	Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial. International Journal of Cardiology, 2016, 212, 110-117.	1.7	26
295	Computing Methods for Composite ClinicalÂEndpoints in Unprotected Left Main Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 2280-2288.	2.9	26
296	The Radial Artery for Percutaneous Coronary Procedures or Surgery?. Journal of the American College of Cardiology, 2018, 71, 1167-1175.	2.8	26
297	Association of acute kidney injury and bleeding events with mortality after radial or femoral access in patients with acute coronary syndrome undergoing invasive management: secondary analysis of a randomized clinical trial. European Heart Journal, 2019, 40, 1226-1232.	2.2	26
298	Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. International Journal of Cardiology, 2020, 301, 200-206.	1.7	26
299	The SYNTAX score on its way out or â€¦ towards artificial intelligence: part I. EuroIntervention, 2020, 16, 44-59.	3.2	26
300	Percutaneous coronary intervention versus bypass surgery for left main coronary artery disease: a meta-analysis of randomised trials. EuroIntervention, 2011, 7, 738-746.	3.2	26
301	Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R). Rationale for the Study and Protocol Design. Cardiovascular Drugs and Therapy, 2008, 22, 313-320.	2.6	25
302	Benefit of radial approach in reducing the incidence of acute kidney injury after percutaneous coronary intervention: A meta-analysis of 22,108 patients. International Journal of Cardiology, 2015, 179, 309-311.	1.7	25
303	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. JAMA Cardiology, 2017, 2, 855.	6.1	25
304	Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management. JACC: Cardiovascular Interventions, 2021, 14, 361-373.	2.9	25
305	Does the site of bleeding matter? A stratified analysis on Flocation of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction. EuroIntervention, 2012, 8, 71-78.	3.2	25
306	Immediate and One-Year Outcome of Percutaneous Intervention of Saphenous Vein Graft Disease With Paclitaxel-Eluting Stents. American Journal of Cardiology, 2005, 96, 395-398.	1.6	24

#	Article	IF	Citations
307	Short and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Journal of Thrombosis and Thrombolysis, 2009, 28, 200-210.	2.1	24
308	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end pointsâ€"Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). American Heart Journal, 2018, 198, 152-159.	2.7	24
309	Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f50-f60.	3.0	24
310	Management of acute coronary syndromes in older adults. European Heart Journal, 2022, 43, 1542-1553.	2.2	24
311	Use of Impella Recover(R) LP 2.5 left ventricular assist device during high-risk percutaneous coronary interventions; clinical, haemodynamic and biochemical findings. EuroIntervention, 2006, 2, 91-100.	3.2	24
312	Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry. Journal of Invasive Cardiology, 2014, 26, 563-9.	0.4	24
313	Acute effects of alcohol septal ablation on systolic and diastolic left ventricular function in patients with hypertrophic obstructive cardiomyopathy. Heart, 2007, 94, 1318-1322.	2.9	23
314	Impact of Sex on 2-Year Clinical OutcomesÂin Patients Treated WithÂ6-Month or 24-Month Dual-Antiplatelet Therapy Duration. JACC: Cardiovascular Interventions, 2016, 9, 1780-1789.	2.9	23
315	Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A study of age- and gender-matched cohorts. International Journal of Cardiology, 2017, 243, 150-155.	1.7	23
316	Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for CoronaryÂRevascularization in RoutineÂClinicalÂPractice. JACC: Cardiovascular Interventions, 2019, 12, 1665-1675.	2.9	23
317	Efficacy and Safety of TicagrelorÂMonotherapy in PatientsÂUndergoing Multivessel PCI. Journal of the American College of Cardiology, 2019, 74, 2015-2027.	2.8	23
318	Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. American Journal of Cardiovascular Drugs, 2019, 19, 173-183.	2.2	23
319	Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 216-226.	3.0	23
320	Sexâ€Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. Journal of the American Heart Association, 2021, 10, e021965.	3.7	23
321	Antithrombotic therapy in TAVI patients: changing concepts. EuroIntervention, 2015, 14, W92-W95.	3.2	23
322	Defining the Role of Platelet Glycoprotein Receptor Inhibitors in STEMI. Drugs, 2009, 69, 85-100.	10.9	22
323	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2018, 11, 53-65.	2.9	22
324	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. European Heart Journal, 2018, 39, e1-e33.	2.2	22

#	Article	IF	Citations
325	Post-Procedural Bivalirudin Infusion atÂFull or Low Regimen in Patients WithÂAcute Coronary Syndrome. Journal of the American College of Cardiology, 2019, 73, 758-774.	2.8	22
326	Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 492-502.	3.0	22
327	Intracardiac echocardiography guidance during percutaneous transluminal septal myocardial ablation in patients with obstructive hypertrophic cardiomyopathy. International Journal of Cardiovascular Interventions, 2005, 7, 134-137.	0.5	21
328	Direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients. International Journal of Cardiology, 2007, 114, 104-105.	1.7	21
329	Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies. Drugs, 2017, 77, 1733-1754.	10.9	21
330	Mechanical complications in patients with ST-segment elevation myocardial infarction: A single centre experience. PLoS ONE, 2019, 14, e0209502.	2.5	21
331	Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent. American Heart Journal, 2021, 231, 147-156.	2.7	21
332	Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions. EuroIntervention, 2021, 17, 59-66.	3.2	21
333	Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. European Heart Journal, 2021, 42, 2973-2985.	2.2	21
334	Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. EuroIntervention, 2017, 13, 78-86.	3.2	21
335	Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. EuroIntervention, 2015, 10, 1015-1021.	3.2	21
336	Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study. EuroIntervention, 2016, 12, 30-37.	3.2	21
337	Persistence of Neointimal Growth 12 Months After Intervention and Occurrence of Delayed Restenosis in Patients With Left Main Coronary Artery Disease Treated With Drug-Eluting Stents. Journal of the American College of Cardiology, 2006, 47, 1491-1494.	2.8	20
338	Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With STâ€“Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation. American Journal of Cardiology, 2017, 120, 1460-1466.	1.6	20
339	Ischemia and Bleeding in CancerÂPatientsÂUndergoing Percutaneous Coronary Intervention. JACC: CardioOncology, 2019, 1, 145-155.	4.0	20
340	Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial. European Heart Journal, 2020, 41, 4497-4504.	2.2	20
341	Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. EuroIntervention, 2020, 15, e1605-e1614.	3.2	20
342	Five-year outcomes of surgical or percutaneous myocardial revascularization in diabetic patients. International Journal of Cardiology, 2013, 168, 1028-1033.	1.7	19

#	Article	IF	Citations
343	Effects of preâ€hospital clopidogrel administration on early and late residual platelet reactivity in STâ€segment elevation myocardial infarction patients undergoing primary intervention. Journal of Thrombosis and Haemostasis, 2013, 11, 192-194.	3.8	19
344	Stable Angina Pectoris. Current Atherosclerosis Reports, 2014, 16, 422.	4.8	19
345	Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term DualÂAntiplateletÂTherapy. JACC: Cardiovascular Interventions, 2017, 10, 1621-1630.	2.9	19
346	Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation. Circulation: Cardiovascular Interventions, 2019, 12, e007541.	3.9	19
347	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. International Journal of Cardiology, 2019, 286, 43-50.	1.7	19
348	Comparing methods for estimating patientâ€specific treatment effects in individual patient data metaâ€analysis. Statistics in Medicine, 2021, 40, 1553-1573.	1.6	19
349	Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: Rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in Uncertain DES Candidates study. American Heart Journal, 2013, 166, 831-838.	2.7	18
350	Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials. Clinical Research in Cardiology, 2016, 105, 575-584.	3.3	18
351	Questions and answers on coronary revascularization: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, e8-e14.	2.2	18
352	Impact of chronic kidney disease on 2â€year clinical outcomes in patients treated with 6â€month or 24â€month DAPT duration: An analysis from the PRODIGY trial. Catheterization and Cardiovascular Interventions, 2017, 90, E73-E84.	1.7	18
353	Shortâ€versus longâ€term Dual Antiplatelet therapy after drugâ€eluting stent implantation in women versus men: A sexâ€specific patientâ€level pooledâ€analysis of six randomized trials. Catheterization and Cardiovascular Interventions, 2017, 89, 178-189.	1.7	18
354	Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 810-822.	4.5	18
355	Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY). BMJ Open, 2019, 9, e026053.	1.9	18
356	Clinical outcomes of Watchman vs. Amplatzer occluders for left atrial appendage closure (WATCH at) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.7	18
357	Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Preâ€Specified Analysis of the GLOBAL LEADERS Trial. Journal of the American Heart Association, 2021, 10, e015560.	3.7	18
358	The SYNTAX score on its way out or â€¦ towards artificial intelligence: part II. EuroIntervention, 2020, 16, 60-75.	3.2	18
359	Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes. EuroIntervention, 2020, 16, 627-633.	3.2	18
360	Watchman FLX vs. Watchman 2.5 in a Dual-Center Left Atrial Appendage Closure Cohort: the WATCH-DUAL study. Europace, 2022, 24, 1441-1450.	1.7	18

#	Article	IF	Citations
361	Impact of drug-eluting stent selection on long-term clinical outcomes in patients treated for unprotected left main coronary artery disease: The sirolimus vs paclitaxel drug-eluting stent for left main registry (SP-DELFT). International Journal of Cardiology, 2009, 137, 16-21.	1.7	17
362	Comparison of the Long-Term Safety and Efficacy of Drug-Eluting and Bare-Metal Stent Implantation in Saphenous Vein Grafts. Circulation: Cardiovascular Interventions, 2010, 3, 249-256.	3.9	17
363	Randomized comparison of operator radiation exposure comparing transradial and transfemoral approach for percutaneous coronary procedures: rationale and design of the minimizing adverse haemorrhagic events by TRansradial access site and systemic implementation of angioX â€“ RAdiation Dose study (RAD-MATRIX). Cardiovascular Revascularization Medicine, 2014, 15, 209-213.	0.8	17
364	Usefulness and Safety of Vorapaxar in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial). American Journal of Cardiology, 2014, 114, 665-673.	1.6	17
365	Everolimus-eluting stent versus bare-metal stent in elderly (â‰¥75years) versus non-elderly (<75years) patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the examination trial. International Journal of Cardiology, 2015, 179, 73-78.	1.7	17
366	Fiveâ€Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimusâ€Eluting Stents Versus Durable Polymer Everolimusâ€Eluting Stents. Journal of the American Heart Association, 2019, 8, e013607.	3.7	17
367	A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making. American Heart Journal, 2020, 223, 44-47.	2.7	17
368	DAPT Score and the Impact of TicagrelorÂMonotherapy During the Second Year After PCI. JACC: Cardiovascular Interventions, 2020, 13, 634-646.	2.9	17
369	Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. EuroIntervention, 2016, 12, e623-e631.	3.2	17
370	A double-blind randomised study to evaluate the efficacy and safety of bindarit in preventing coronary stent restenosis. EuroIntervention, 2016, 12, e1385-e1394.	3.2	17
371	Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: Evidence from a meta-regression. American Heart Journal, 2007, 153, 587-593.	2.7	16
372	Evaluation of Platelet Inhibition by Tirofiban in Patients Stratified According to Aspirin and Clopidogrel Responsiveness. Journal of the American College of Cardiology, 2010, 55, 255-256.	2.8	16
373	How can we optimize the processes of care for acute coronary syndromes to improve outcomes?. American Heart Journal, 2014, 168, 622-631.e2.	2.7	16
374	Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization. Journal of Cardiovascular Translational Research, 2015, 8, 211-220.	2.4	16
375	Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions. Netherlands Heart Journal, 2015, 23, 153-160.	0.8	16
376	Effect of Diabetes Mellitus on Frequency of Adverse Events in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2016, 118, 345-352.	1.6	16
377	The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short. Cardiovascular Diagnosis and Therapy, 2018, 8, 630-646.	1.7	16
378	Impact of left ventricular function on clinical outcomes among patients with coronary artery disease. European Journal of Preventive Cardiology, 2019, 26, 1273-1284.	1.8	16

#	Article	IF	Citations
379	Clinical relevance of ticagrelor monotherapy following 1â€month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2020, 96, 100-111.	1.7	16
380	Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. EuroIntervention, 2019, 15, e539-e546.	3.2	16
381	High-Dose BoluS TiRofibAn and Sirolimus Eluting STEnt versus Abiciximab and Bare Metal Stent in Acute MYocardial Infarction (STRATEGY) Studyâ€"Protocol Design and Demography of the First 100 Patients. Cardiovascular Drugs and Therapy, 2004, 18, 225-230.	2.6	15
382	Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction. American Heart Journal, 2007, 154, 39-45.	2.7	15
383	Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI. Journal of Thrombosis and Haemostasis, 2008, 6, 1824-1826.	3.8	15
384	Effects of Percutaneous Transluminal Septal Myocardial Ablation for Obstructive Hypertrophic Cardiomyopathy on Systolic and Diastolic Left Ventricular Function Assessed by Pressureâ€"Volume Loops. American Journal of Cardiology, 2008, 101, 1179-1184.	1.6	15
385	Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study. Journal of Cardiovascular Translational Research, 2016, 9, 249-256.	2.4	15
386	Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e009177.	3.9	15
387	Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With STâ€Segmentâ€"Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Longâ€Term Followâ€Up of the REDUCEâ€MVI Trial. Journal of the American Heart Association, 2020, 9, e014411.	3.7	15
388	In vivo relationship between compositional and mechanical imaging of coronary arteries. American Heart Journal, 2006, 151, 1025.e1-1025.e6.	2.7	14
389	Randomized, doubleâ€blind comparison of effects of abciximab bolus only vs. onâ€label regimen on exÂvivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting. Journal of Thrombosis and Haemostasis, 2010, 8, 1903-1911.	3.8	14
390	Acute kidney injury after primary angioplasty. Journal of Cardiovascular Medicine, 2014, 15, 60-67.	1.5	14
391	Comparison of Percutaneous Coronary Intervention (With Drug-Eluting Stents) Versus Coronary Artery Bypass Grafting in Women With Severe Narrowing of the Left Main Coronary Artery (from the) Tj ETQq1 1 0.784314 rgBT /Ove Cardiology, 2014, 113, 1348-1355.	1.6	14
392	Bivalirudin versus heparin in patients with acute myocardial infarction: A metaâ€analysis of randomized trials. Catheterization and Cardiovascular Interventions, 2015, 86, 378-389.	1.7	14
393	Cardiac Nerve Growth Factor Overexpression Induces Bone Marrowâ€"derived Progenitor Cells Mobilization and Homing to the Infarcted Heart. Molecular Therapy, 2015, 23, 1854-1866.	8.2	14
394	Developing drugs for use before, during and soon after percutaneous coronary intervention. Expert Opinion on Pharmacotherapy, 2016, 17, 803-818.	1.8	14
395	Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors. Clinical Research in Cardiology, 2017, 106, 165-173.	3.3	14
396	The ESC DAPT Guidelines 2017. European Heart Journal, 2018, 39, 187-188.	2.2	14

#	Article	IF	Citations
397	Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovascular Diabetology, 2020, 19, 179.	6.8	14
398	Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. Clinical Research in Cardiology, 2020, 109, 930-943.	3.3	14
399	Bleeding risk prediction in elderly patients managed invasively for acute coronary syndromes: External validation of the PRECISE-DAPT and PARIS scores. International Journal of Cardiology, 2021, 328, 22-28.	1.7	14
400	Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis. Clinical Research in Cardiology, 2021, 110, 831-840.	3.3	14
401	The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. Clinical Research in Cardiology, 2020, 109, 1125-1139.	3.3	14
402	Left ventricular volumes in liver cirrhosis. Digestive and Liver Disease, 2000, 32, 392-397.	0.9	13
403	Triple Antiplatelet Therapy in Acute Coronary Syndromes. Drugs, 2011, 71, 1703-1719.	10.9	13
404	Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial. American Heart Journal, 2012, 163, 104-111.	2.7	13
405	Effects of Ticagrelor, Prasugrel, or Clopidogrel at Steady State on Endothelial Function. Journal of the American College of Cardiology, 2018, 71, 1289-1291.	2.8	13
406	Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization. Circulation: Cardiovascular Interventions, 2018, 11, e006741.	3.9	13
407	Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. Thrombosis and Haemostasis, 2020, 120, 348-362.	3.4	13
408	Long-Term Prognostic Impact of Restenosis of the Unprotected Left Main Coronary Artery Requiring Repeat Revascularization. JACC: Cardiovascular Interventions, 2020, 13, 2266-2274.	2.9	13
409	Impact of Echocardiographic Guidance on Safety and Efficacy of Left Atrial Appendage Closure. JACC: Cardiovascular Interventions, 2021, 14, 1815-1826.	2.9	13
410	Prediction of radial crossover in acute coronary syndromes: derivation and validation of the MATRIX score. EuroIntervention, 2021, 17, e971-e980.	3.2	13
411	Different clinical models of CD34Â+Âcells mobilization in patients with cardiovascular disease. Journal of Thrombosis and Thrombolysis, 2011, 32, 1-8.	2.1	12
412	Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the VIP) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 142 T 792-798.	1.6	12
413	Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multivessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	12
414	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. Circulation: Cardiovascular Interventions, 2016, 9, e002995.	3.9	12

#	Article	IF	Citations
415	Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy. International Journal of Cardiology, 2017, 229, 82-89.	1.7	12
416	The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. European Journal of Preventive Cardiology, 2018, 25, 377-387.	1.8	12
417	A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. Canadian Journal of Cardiology, 2020, 36, 1298-1307.	1.7	12
418	Sexâ€Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patientâ€Level Pooled Analysis From 4 Postapproval Studies. Journal of the American Heart Association, 2020, 9, e014611.	3.7	12
419	Assessing the cardiology community position on transradial intervention and the use of bivalirudin in patients with acute coronary syndrome undergoing invasive management: results of an EAPCI survey. EuroIntervention, 2016, 12, 1154-1163.	3.2	12
420	Title is missing!. European Heart Journal Supplements, 2004, 6, F22-F29.	0.1	11
421	Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: The INtegrilin plus STenting to Avoid myocardial Necrosis Trial. American Heart Journal, 2012, 163, 835.e1-835.e7.	2.7	11
422	Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction. International Journal of Cardiology, 2013, 168, 2632-2636.	1.7	11
423	Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Thrombosis and Haemostasis, 2015, 114, 933-944.	3.4	11
424	Anatomic Characteristics and Clinical Implications of Angiographic Coronary Thrombus. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	11
425	Current know how on the absorb BVS technology: An experts' survey. International Journal of Cardiology, 2015, 180, 203-205.	1.7	11
426	External validity of the â€œall-comersâ€•design: insights from the BIOSCIENCE trial. Clinical Research in Cardiology, 2016, 105, 744-754.	3.3	11
427	Questions and answers on diagnosis and risk assessment: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, e15-e21.	2.2	11
428	Computed tomography detection and quantification of left atrial appendage residual patency as collateral finding after percutaneous closure. International Journal of Cardiology, 2018, 260, 42-46.	1.7	11
429	Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 158-163.	3.0	11
430	Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006660.	2.2	11
431	Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. European Journal of Preventive Cardiology, 2021, 28, 432-445.	1.8	11
432	Comparative frequency and prognostic impact of myocardial injury in hospitalized patients with COVID-19 and Influenza. European Heart Journal Open, 2021, 1, .	2.3	11

#	Article	IF	Citations
433	Incidence and impact of renal dysfunction on clinical outcomes after transcatheter aortic valve implantation. International Journal of Cardiology, 2018, 250, 73-79.	1.7	11
434	A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. EuroIntervention, 2018, 14, 692-699.	3.2	11
435	Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk. Journal of the American College of Cardiology, 2021, 78, 1968-1986.	2.8	11
436	Duplex Doppler findings in splenic arteriovenous fistula. , 1998, 26, 103-105.		10
437	Acute coronary syndromes: an emphasis shift from treatment to prevention; and the enduring challenge of vulnerable plaque detection in the cardiac catheterization laboratory. Journal of Cardiovascular Medicine, 2007, 8, 221-229.	1.5	10
438	Drug-Eluting Stents Versus Bare-Metal Stents in Diabetic Patients With ST-Segment Elevation Acute Myocardial Infarction: A Pooled Analysis of Individual Patient Data From 7 Randomized Trials. Revista Espanola De Cardiologia (English Ed), 2009, 62, 354-364.	0.6	10
439	Radial versus femoral access for cardiac catheterisation â€“ Authors' reply. Lancet, The, 2015, 386, 2394.	13.7	10
440	Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Cardiology, 2018, 121, 1039-1045.	1.6	10
441	Use of PRECISE-DAPT Score and Admission Platelet Count to Predict Mortality Risk in Patients With Acute Coronary Syndrome. Angiology, 2019, 70, 867-877.	1.8	10
442	The remarkable story of a wonder drug, which now comes to an end in the primary prevention setting: say bye-bye to aspirin!. European Heart Journal, 2019, 40, 618-620.	2.2	10
443	Comparison of Investigator-Reported and Clinical Event Committeeâ€“Adjudicated Outcome Events in GLASSY. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006581.	2.2	10
444	Prognostic impact of invasive haemodynamic measurements in combination with clinical and echocardiographic characteristics on two-year clinical outcomes of patients undergoing transcatheter aortic valve implantation. EuroIntervention, 2017, 12, e2186-e2193.	3.2	10
445	Clinical and echocardiographic risk factors for device-related thrombus after left atrial appendage closure: an analysis from the multicenter EUROC-DRT registry. Clinical Research in Cardiology, 2022, 111, 1276-1285.	3.3	10
446	What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. QJM - Monthly Journal of the Association of Physicians, 2010, 103, 367-377.	0.5	9
447	Everolimus-Eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study. Journal of Cardiovascular Translational Research, 2016, 9, 40-48.	2.4	9
448	Costâ€effectiveness of percutaneous coronary intervention with cobaltâ€chromium everolimus eluting stents versus bare metal stents: Results from a patient level metaâ€analysis of randomized trials. Catheterization and Cardiovascular Interventions, 2017, 89, 994-1002.	1.7	9
449	Antithrombotic therapy after transcatheter aortic valve implantation: a new piece of the still unresolved puzzle. Journal of Thoracic Disease, 2017, 9, 4260-4265.	1.4	9
450	Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease. American Heart Journal, 2018, 197, 103-112.	2.7	9

#	Article	IF	Citations
451	Effects of Fentanyl Versus Morphine on Ticagrelor-Induced Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction. Circulation, 2020, 142, 2479-2481.	1.6	9
452	Choices in antithrombotic management for patients with atrial fibrillation undergoing percutaneous coronary intervention: questions (and answers) in chronological sequence. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 68-73.	3.0	9
453	The conundrum of antithrombotic drugs before, during and after primary PCI. EuroIntervention, 2014, 10, T64-T73.	3.2	9
454	Latest Clinical Data on Testing for High On-Treatment Platelet Reactivity. Reviews in Cardiovascular Medicine, 2011, 12, 14-22.	1.4	9
455	Abciximab: a reappraisal of its use in coronary care. Biologics: Targets and Therapy, 2008, 2, 29.	3.2	8
456	Longâ€term outcome after percutaneous coronary intervention in patients with essential thrombocythemia. Journal of Thrombosis and Haemostasis, 2009, 7, 1235-1238.	3.8	8
457	Randomized evaluation of intracoronary nitroprusside vs. adenosine after thrombus aspiration during primary percutaneous coronary intervention for the prevention of no-reflow in acute myocardial infarction: the REOPEN-AMI study protocol. Journal of Cardiovascular Medicine, 2009, 10, 585-592.	1.5	8
458	Rationale and study design of the <scp>RESERVOIR</scp> trial: A randomized trial comparing reservoirâ€based polymerâ€free amphilimusâ€eluting stents versus everolimusâ€eluting stents with durable polymer in patients with diabetes mellitus. Catheterization and Cardiovascular Interventions, 2015, 85, E116-22.	1.7	8
459	Impact of Clinical PresentationÂon Dual AntiplateletÂTherapy Duration. Journal of the American College of Cardiology, 2015, 66, 1203-1204.	2.8	8
460	Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and ClinicalÂOutcomes in Patients With AcuteÂCoronary Syndrome. JACC: Cardiovascular Interventions, 2016, 9, 1667-1676.	2.9	8
461	Rationale and design of the Hunting for the off-target propertIes of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial. American Heart Journal, 2017, 189, 128-136.	2.7	8
462	Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 352-359.	3.0	8
463	Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. European Heart Journal, 2022, 43, 940-958.	2.2	8
464	Ischaemic and bleeding risk in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: is it time to REACT?. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 1125-1128.	1.0	8
465	Sex differences in distribution, management and outcomes of combined ischemic-bleeding risk following acute coronary syndrome. International Journal of Cardiology, 2021, 329, 16-22.	1.7	8
466	Coronary stent selection and optimal course of dual antiplatelet therapy in patients at high bleeding or thrombotic risk. Current Opinion in Cardiology, 2015, 30, 325-332.	1.8	8
467	Impact of stent overlapping on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction: insights from the five-year follow-up of the EXAMINATION trial. EuroIntervention, 2017, 13, e557-e563.	3.2	8
468	In-hospital management and outcome of patients on warfarin undergoing coronary stent implantation: results of the multicenter, prospective WARfarin and coronary STENTing (WAR-STENT) registry. Journal of Invasive Cardiology, 2013, 25, 170-6.	0.4	8

#	Article	IF	Citations
469	Carotid Stent Cell Design: Lack of Benefit or Lack of Evidence?. Stroke, 2008, 39, e130; author reply e133.	2.0	7
470	Two-year outcomes after first- or second-generation drug-eluting stent implantation in patients with in-stent restenosis. A PRODIGY trial substudy. International Journal of Cardiology, 2014, 173, 343-345.	1.7	7
471	Effectiveness of Pretreatment With Dual Oral Antiplatelet Therapy. American Journal of Cardiology, 2015, 116, 660-668.	1.6	7
472	Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with primary angioplasty: Results of an angiographic randomized pilot study. Catheterization and Cardiovascular Interventions, 2016, 87, 1187-1193.	1.7	7
473	Determinants of radiation dose during right transradial access: Insights from the RAD-MATRIX study. American Heart Journal, 2018, 196, 113-118.	2.7	7
474	2017 European Society of Cardiology (ESC) focused update on dual antiplatelet therapy in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Journal of Cardio-thoracic Surgery, 2018, 53, 3-4.	1.4	7
475	ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial. Journal of Electrocardiology, 2019, 57, 44-54.	0.9	7
476	Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 222-230.	3.0	7
477	Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 22-30.	3.0	7
478	Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. Revista Espanola De Cardiologia (English Ed), 2020, 73, 893-901.	0.6	7
479	Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale. Journal of Cardiovascular Translational Research, 2021, 14, 110-119.	2.4	7
480	Design and Rationale of the Swiss-Apero Randomized Clinical Trial: Comparison of Amplatzer Amulet vs Watchman Device in Patients Undergoing Left Atrial Appendage Closure. Journal of Cardiovascular Translational Research, 2021, 14, 930-940.	2.4	7
481	Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial. EuroIntervention, 2018, 13, 1939-1945.	3.2	7
482	Myocardial ischaemia: new evidence for angiotensin-converting enzyme inhibition. European Heart Journal Supplements, 2003, 5, E11-E17.	0.1	6
483	Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Unprotected Left Main Coronary Artery Disease: The Endless Debate. Journal of the American College of Cardiology, 2008, 52, 582-584.	2.8	6
484	Safety evaluation of tirofiban. Expert Opinion on Drug Safety, 2010, 9, 801-819.	2.4	6
485	Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: Balancing safety and efficacy. American Heart Journal, 2010, 160, S36-S41.	2.7	6
486	Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2019, 12, e007734.	3.9	6

#	Article	IF	Citations
487	Femoral Access With or Without Vascular Closure Device or RadialÂAccess in Acute Coronary Syndrome. JACC: Cardiovascular Interventions, 2019, 12, 2116-2118.	2.9	6
488	Does Large Vessel Size Justify Use of Bare-Metal Stents in Primary Percutaneous Coronary Intervention?. Circulation: Cardiovascular Interventions, 2019, 12, e007705.	3.9	6
489	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. Catheterization and Cardiovascular Interventions, 2020, 96, 1369-1378.	1.7	6
490	Device profile of the XIENCE V and XIENCE Sierra stents for the treatment of coronary artery disease: an overview of safety and efficacy. Expert Review of Medical Devices, 2020, 17, 383-390.	2.8	6
491	Predicting 2â€year allâ€cause mortality after contemporary <scp>PCI</scp>: Updating the logistic clinical <scp>SYNTAX</scp> score. Catheterization and Cardiovascular Interventions, 2021, 98, 1287-1297.	1.7	6
492	From secondary to tertiary mitral regurgitation: the paradigm shifts, but uncertainties remain. European Heart Journal Cardiovascular Imaging, 2021, 22, 835-843.	1.2	6
493	Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. International Journal of Cardiology, 2021, 337, 1-8.	1.7	6
494	Dual Antiplatelet Therapy After Drug-eluting Stent Implantation. Interventional Cardiology Review, 2016, 11, 51.	1.6	6
495	Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial. EuroIntervention, 2020, 16, 634-644.	3.2	6
496	Optical coherence tomography appraisal of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing intraprocedural versus post-stenting prolonged bivalirudin infusion. Rationale and design of the MATRIX (Minimizing Adverse Haemorrhagic Events by) Tj ETQq0 0 0 rgBT /Overlock 10 T	3.2	6
497	â€œTailoredâ€•antiplatelet bridging therapy with cangrelor: moving toward personalized medicine. Platelets, 2022, 33, 687-691.	2.3	6
498	Revisiting the incidence and temporal distribution of cardiac and sudden death in patients undergoing elective intervention for unprotected left main coronary artery stenosis in the drug eluting stent era. EuroIntervention, 2007, 2, 435-43.	3.2	6
499	A prospective, first-in-human use of the NeVa mechanical thrombectomy device for patients with acute coronary syndromes. EuroIntervention, 2022, 18, 242-252.	3.2	6
500	Neurohormones, cytokines and programmed cell death in heart failure: a new paradigm for the remodeling heart. Cardiovascular Drugs and Therapy, 2001, 15, 529-537.	2.6	5
501	Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents?. Journal of Cardiovascular Medicine, 2009, 10, S17-S26.	1.5	5
502	Tailored Medical and Interventional Therapy Against Recurrent Stent Thrombosis After Drug-Eluting Stenting. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 591-593.	1.7	5
503	Dual antiplatelet therapy duration. Current Opinion in Cardiology, 2011, 26, S4-S14.	1.8	5
504	Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: A meta-analysis of randomized trials. International Journal of Cardiology, 2012, 155, 243-248.	1.7	5

#	Article	IF	Citations
505	Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction. American Heart Journal, 2013, 166, 119-126.e1.	2.7	5
506	Current-era biovascular scaffolds seen by experts: An experience-based survey. International Journal of Cardiology, 2015, 188, 16-18.	1.7	5
507	Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial. International Journal of Cardiology, 2015, 190, 242-245.	1.7	5
508	Bivalirudin in Current Practice. JACC: Cardiovascular Interventions, 2016, 9, 1321-1323.	2.9	5
509	Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). American Journal of Cardiology, 2019, 124, 1833-1840.	1.6	5
510	Comparison of intra-procedural vs. post-stenting prolonged bivalirudin infusion for residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing: the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) OCT study. European Heart Journal Cardiovascular Imaging, 2019, 20, 1418-1428.	1.2	5
511	Application of the MADS classification system in a â€œmega mammothâ€•stent trial: Feasibility and preliminary clinical implications. Catheterization and Cardiovascular Interventions, 2019, 93, 57-63.	1.7	5
512	Lugar de acceso y tipo de anticoagulante en pacientes con sÃndrome coronario agudo en clase Killip avanzada o con parada cardiaca extrahospitalaria. Revista Espanola De Cardiologia, 2020, 73, 893-901.	1.2	5
513	Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006582.	2.2	5
514	Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2020, 96, E516-E526.	1.7	5
515	Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial. Cardiovascular Revascularization Medicine, 2022, 34, 3-10.	0.8	5
516	Cardiovascular mortality and morbidity in patients undergoing percutaneous coronary intervention after out-of-hospital cardiac arrest: a systematic review and meta-analysis. EuroIntervention, 2021, 16, e1245-e1253.	3.2	5
517	Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update. EuroIntervention, 2010, 6, 39-45.	3.2	5
518	Sex Differences in Outcomes After Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Left Main Disease: From the DELTA Registries. Journal of the American Heart Association, 2022, 11, e022320.	3.7	5
519	Letters Regarding Article by Patti et al, â€œRandomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	4
520	Paclitaxel eluting stents for the treatment of angiographically nonâ€•significant atherosclerotic lesions. International Journal of Cardiovascular Interventions, 2005, 7, 68-71.	0.5	4
521	Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after myocardial infarction. European Heart Journal Supplements, 2008, 10, K27-K34.	0.1	4
522	A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial. Journal of Cardiovascular Medicine, 2008, 9, 957-962.	1.5	4

#	Article	IF	Citations
523	Peri-procedural myocardial infarction and troponism: a quick journey through the land of confusion. Heart, 2012, 98, 1400-1401.	2.9	4
524	Identifying responsiveness to oral P2Y12 receptor blockers. Journal of Cardiovascular Medicine, 2013, 14, S8-S15.	1.5	4
525	Efficacy of Radial Versus Femoral Access in the Acute Coronary Syndrome. JACC: Cardiovascular Interventions, 2016, 9, 978-979.	2.9	4
526	Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease. Current Cardiology Reports, 2017, 19, 2.	2.9	4
527	Longâ€term prognostic value of risk scores after drugâ€eluting stent implantation for unprotected left main coronary artery: A pooled analysis of the ISARâ€LEFTâ€MAIN and ISARâ€LEFTâ€MAIN 2 randomized clinical trials. Catheterization and Cardiovascular Interventions, 2017, 89, 1-10.	1.7	4
528	Activated Clotting Time During Unfractionated Heparin-Supported Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 1046-1049.	2.9	4
529	Prognostic Relevance of Left Ventricular Myocardial Performance After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2019, 12, e006612.	3.9	4
530	Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial. International Journal of Cardiology, 2020, 320, 27-34.	1.7	4
531	Usefulness of updated logistic clinical SYNTAX score based on MIâ€SYNTAX score in patients with STâ€elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2021, 97, E919-E928.	1.7	4
532	Regional variation in patients and outcomes in the GLOBAL LEADERS trial. International Journal of Cardiology, 2021, 324, 30-37.	1.7	4
533	Composition, structure, and function of heart teams: a joint position paper of the ACVC, EAPCI, EACTS, and EACTA focused on the management of patients with complex coronary artery disease requiring myocardial revascularization. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 83-93.	1.0	4
534	Large-Bore Radial Access for Complex PCI. JACC: Cardiovascular Interventions, 2021, 14, 1304-1307.	2.9	4
535	Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 1170-1179.	1.0	4
536	Appraising the safety and efficacy profile of left atrial appendage closure in 2016 and the future clinical perspectives. Results of the EAPCI LAAC survey. EuroIntervention, 2016, 12, 112-118.	3.2	4
537	Cardiovascular risk profile of patients included in stent trials; a pooled analysis of individual patient data from randomised clinical trials: insights from 33 prospective stent trials in Europe. EuroIntervention, 2011, 7, 859-871.	3.2	4
538	Deferred angioplasty and stenting in primary percutaneous coronary intervention: one step back, two steps forward?. EuroIntervention, 2013, 8, 1119-1123.	3.2	4
539	Quantification of scientific output in cardiovascular medicine: a perspective based on global data. EuroIntervention, 2013, 9, 975-978.	3.2	4
540	Drugâ€Eluting or Bareâ€Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization. Journal of the American Heart Association, 2021, 10, e018828.	3.7	4

#	Article	IF	Citations
541	Validation and Additive Predictive Value of the Academic Research Consortiumâ€"High Bleeding Risk Criteria in Older Adults. Thrombosis and Haemostasis, 2021, 121, 1255-1257.	3.4	4
542	The impact of the COVID-19 pandemic upon patients, staff, and on the future practices of percutaneous coronary intervention. European Heart Journal Supplements, 2020, 22, P13-P18.	0.1	4
543	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drugâ€Eluting Stent Implantation: Perâ€Protocol Analysis of the GLOBAL LEADERS Trial. Journal of the American Heart Association, 2022, 11, e024291.	3.7	4
544	Left ventricular thrombus in ischaemic heart disease: diagnosis, treatment, and gaps of knowledge. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 496-509.	4.0	4
545	Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2022, 100, 72-82.	1.7	4
546	Comparative Outcomes After Percutaneous Coronary Intervention in Unconscious and Conscious Patients WithÂOut-of-Hospital Cardiac Arrest. JACC: Cardiovascular Interventions, 2022, 15, 1338-1348.	2.9	4
547	Temporal and Genotype-Driven Variation of Factor VII Levels in Patients With Acute Myocardial Infarction. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 119-122.	1.7	3
548	Comparison of Bivalirudin Versus Heparin(s) During Percutaneous Coronary Interventions in Patients Receiving Prasugrel: A Propensityâ€Matched Study. Clinical Cardiology, 2014, 37, 14-20.	1.8	3
549	Digital Gangrene Following Transradial Coronary Angiogram. JACC: Cardiovascular Interventions, 2016, 9, 980-981.	2.9	3
550	DAPT Duration After Drug-Eluting StentÂImplantation. JACC: Cardiovascular Interventions, 2017, 10, 1211-1214.	2.9	3
551	Deciding on the Duration of Dual Antiplatelet Therapyâ€"When the Choice Between 2 Evils Is Still Evil. JAMA Cardiology, 2017, 2, 488.	6.1	3
552	Development and validation of a risk model for longâ€term mortality after percutaneous coronary intervention: The IDEAâ€BIO Study. Catheterization and Cardiovascular Interventions, 2018, 91, 686-695.	1.7	3
553	Chronic Thrombocytopenia and Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 1869-1871.	2.9	3
554	Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial. PLoS ONE, 2018, 13, e0201985.	2.5	3
555	OCT Appraisal of Residual Thrombus Burden in Patients With STEMI Undergoing Intraprocedural Versus Post-Stenting ProlongedÂBivalirudin Infusion. JACC: Cardiovascular Imaging, 2019, 12, 934-936.	5.3	3
556	Obstructive sleep apnoea syndrome and endothelial function: potential impact of different treatment strategiesâ€"meta-analysis of prospective studies. European Archives of Oto-Rhino-Laryngology, 2019, 276, 2331-2338.	1.6	3
557	Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. Clinical Research in Cardiology, 2020, 109, 918-929.	3.3	3
558	Higher risk of stent thrombosis with double therapy with direct oral anticoagulants: cherry picking the populations of interest does not help. European Heart Journal, 2020, 41, 1701-1702.	2.2	3

#	Article	IF	Citations
559	Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.4	3
560	Composition, structure, and function of heart teams: a joint position paper of the ACVC, EAPCI, EACTS, and EACTA focused on the management of patients with complex coronary artery disease requiring myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2021, 59, 522-531.	1.4	3
561	Single antiplatelet therapy with use of prasugrel in patients undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2021, 98, E213-E221.	1.7	3
562	Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry. Minerva Cardiology and Angiology, 2021, 69, 408-416.	0.7	3
563	A call for action in bleeding prevention. Aging, 2019, 11, 287-288.	3.1	3
564	A new iteration for the single-access large-bore technique during Impella supported complex and high-risk coronary intervention: a case report. European Heart Journal - Case Reports, 2021, 5, ytab428.	0.6	3
565	Self-reported non-adherence to P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: Application of the medication non-adherence academic research consortium classification. PLoS ONE, 2022, 17, e0263180.	2.5	3
566	Radial vs Femoral Access in ACS Patients Undergoing Complex PCI Is Associated With Consistent Bleeding Benefit and No Excess of Risks. Canadian Journal of Cardiology, 2022, 38, 1488-1500.	1.7	3
567	A case of extracranial vertebral artery dissection with spontaneous recovery. European Journal of Ultrasound: Official Journal of the European Federation of Societies for Ultrasound in Medicine and Biology, 1997, 6, 197-201.	1.3	2
568	Tirofiban: a critical reappraisal of the clinical use, recent developments and future perspectives. Future Cardiology, 2006, 2, 17-27.	1.2	2
569	Keeping a high standard in quantitative analyses, meta-analyses, and systematic reviews. European Heart Journal, 2007, 28, 516-517.	2.2	2
570	Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban. Journal of Blood Medicine, 2010, 1, 61.	1.7	2
571	ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome. European Heart Journal Supplements, 2014, 16, C2-C28.	0.1	2
572	Shifting the Focus to Recurrences. JACC: Cardiovascular Interventions, 2014, 7, 1114-1116.	2.9	2
573	Questions and answers on antithrombotic therapy: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, e1-e7.	2.2	2
574	Influence of operator experience and PCI volume on transfemoral access techniques: A collaboration of international cardiovascular societies. Cardiovascular Revascularization Medicine, 2018, 19, 143-150.	0.8	2
575	Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. International Journal of Cardiology, 2019, 277, 60-65.	1.7	2
576	Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS. Canadian Journal of Cardiology, 2020, 36, 747-755.	1.7	2

#	Article	IF	Citations
577	Assessment of residual thrombus burden in patients with STâ€segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Cardiovascular Interventions, 2020, 96, 1156-1171.	1.7	2
578	Intolerance to aspirin in patients undergoing percutaneous coronary intervention in the setting of chronic coronary syndromes: perspectives from the ESC 2019 Chronic Coronary Syndromes guidelines. European Heart Journal, 2020, 41, 483-484.	2.2	2
579	Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimusâ€eluting stents. Catheterization and Cardiovascular Interventions, 2021, 98, 1111-1119.	1.7	2
580	Impact of individual stroke risk on outcome after Amplatzer left atrial appendage closure in patients with atrial fibrillation. Catheterization and Cardiovascular Interventions, 2021, 97, E1002-E1010.	1.7	2
581	Discharge Location and Outcomes After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2021, 140, 95-102.	1.6	2
582	The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registry. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 28-33.	4.0	2
583	Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies. Journal of Thrombosis and Thrombolysis, 2021, 52, 419-428.	2.1	2
584	Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial. International Journal of Cardiology, 2021, 334, 37-41.	1.7	2
585	Clinical impact of left atrial appendage filling defects in patients undergoing transcatheter aortic valve implantation. European Heart Journal Cardiovascular Imaging, 2022, 23, 1354-1364.	1.2	2
586	Impact of sex on comparative outcomes of bivalirudin versus unfractionated heparin in patients with acute coronary syndromes undergoing invasive management: a pre-specified analysis of the MATRIX trial. EuroIntervention, 2019, 15, e269-e278.	3.2	2
587	Time for science to catch up with clinical practice?. Journal of Thoracic Disease, 2015, 7, E603-6.	1.4	2
588	Distal Transradial Access for CoronaryÂProcedures. JACC: Cardiovascular Interventions, 2022, 15, 33-38.	2.9	2
589	Not only lungs: COVID-19 hits platelets as well. European Heart Journal, 2022, 43, 2092-2093.	2.2	2
590	Bivalirudin in Acute Coronary Syndromes. Authors reply. New England Journal of Medicine, 2016, 374, 285-6.	27.0	2
591	Splanchnic arterial doppler parameters in portal hypertension. Hepatology, 1999, 29, 1610-1610.	7.3	1
592	New and old strategies to afford the liberal use of drug-eluting stents in real-life scenarios. Country Review Ukraine, 2005, 7, K31-K35.	0.8	1
593	Complete myocardial revascularization: between myth and reality. European Heart Journal, 2005, 26, 1809-1810.	2.2	1
594	Plaque sealing: Are the benefits outweighing the risks?. International Journal of Cardiology, 2007, 115, 265-266.	1.7	1

#	Article	IF	Citations
595	Clinical Implications of the PROTECTâ€“TIMI-30 Trial. Journal of the American College of Cardiology, 2007, 49, 729-730.	2.8	1
596	A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction. International Journal of Cardiology, 2008, 128, 53-61.	1.7	1
597	Long-term dual antiplatelet therapy and concomitant optimal medical therapy following percutaneous coronary intervention. Cardiovascular Diagnosis and Therapy, 2017, 7, S102-S106.	1.7	1
598	Operators' experience with radial access for cardiac catheterization in patients with acute coronary syndromes. International Journal of Cardiology, 2018, 257, 35.	1.7	1
599	TCT-539 Clinical outcomes in high bleeding risk patients undergoing complex PCI with the Xience everolimus eluting stent: a patient-level pooled analysis from four Xience post-approval trials. Journal of the American College of Cardiology, 2018, 72, B217.	2.8	1
600	Reply. Journal of the American College of Cardiology, 2019, 74, 162-163.	2.8	1
601	PREDICTIVE ABILITY OF THE PARIS RISK SCORE IN ALL-COMERS PATIENTS UNDERGOING PCI WITH DRUG ELUTING STENTS: EXTERNAL VALIDATION IN THE GLOBAL LEADERS STUDY. Journal of the American College of Cardiology, 2019, 73, 245.	2.8	1
602	The Use of Radial Access for Cardiac Catheterization. JACC: Cardiovascular Interventions, 2019, 12, 2257-2259.	2.9	1
603	Ticagrelor in patients with diabetes and previous PCI. Lancet, The, 2019, 394, 1118-1120.	13.7	1
604	Impact of optical coherence tomography findings on clinical outcomes in ST-segment elevation myocardial infarction patients: a MATRIX (Minimizing Adverse Hemorrhagic Events by Trans-radial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1143-1150.	1.5	1
605	External validation of the GRACE risk score 2.0 in the contemporary allâ€comers GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2021, 98, E513-E522.	1.7	1
606	Subcutaneous RUC-4 for acute myocardial infarction: a new treatment on the horizon for pre-hospital care?. EuroIntervention, 2021, 17, e362-e363.	3.2	1
607	Looking back into the future: desirudin in acute coronary syndromes and coronary stenting. EuroIntervention, 2011, 7, 263-269.	3.2	1
608	Bivalirudin versus unfractionated heparin in percutaneous coronary interventions of patients having received initial fondaparinux treatment: a propensity matched study. EuroIntervention, 2012, 8, 486-492.	3.2	1
609	Meeting the Unmet â€“ The Cre8 Polymer-free Drug-eluting Stents Technology. Interventional Cardiology Review, 2014, 9, 184.	1.6	1
610	How should I treat this unusual anterolateral ST-elevation myocardial infarction with recurrent ventricular fibrillation and cardiac arrest?. EuroIntervention, 2016, 12, 928-932.	3.2	1
611	Patients With Atrial Fibrillation and PCI or ACS. Journal of the American College of Cardiology, 2022, 79, 428-431.	2.8	1
612	Radial versus femoral approach in STEMI: what do we know so far?. Minerva Cardioangiologica, 2016, 64, 219-37.	1.2	1

#	Article	IF	Citations
613	Drawbacks of Nonrandomized Trials in Acute Coronary Syndromes. American Journal of Cardiology, 2006, 97, 151.	1.6	0
614	From Chaotic to Coordinated Clinical Research: The Case of Acetylcysteine. Archives of Internal Medicine, 2006, 166, 1668.	3.8	0
615	The heart of coronary arteries. European Heart Journal, 2007, 28, 2063-2063.	2.2	0
616	Use of granulocyte colony-stimulating factor during acute MI: Fact or fiction?. Journal of Molecular and Cellular Cardiology, 2008, 44, 436.	1.9	0
617	A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial. Journal of Cardiovascular Medicine, 2008, Publish Ahead of Print, .	1.5	0
618	Response to Letter Regarding Article, â€œIntensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Studyâ€• Circulation, 2010, 121, .	1.6	0
619	Clinical dilemmas on managing antiplatelet therapies after percutaneous coronary intervention. Current Opinion in Cardiology, 2011, 26, S1-S3.	1.8	0
620	Letter by Cortese and Valgimigli Regarding Article, â€œAntithrombotic Therapy in Patients With Chronic Kidney Diseaseâ€• Circulation, 2012, 126, e333; author reply e334.	1.6	0
621	Letter by Vranckx and Valgimigli Regarding Article, â€œValidation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Interventionâ€• Circulation, 2012, 126, e276; author reply e277.	1.6	0
622	TCT-447 Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction. Insights from the EXAMINATION trial. Journal of the American College of Cardiology, 2013, 62, B138.	2.8	0
623	TCT-242 Impact of gender on clinical outcome of everolimus-eluting stent versus bare-metal stent in patients with ST-elevation myocardial infarction.. Journal of the American College of Cardiology, 2013, 62, B79-B80.	2.8	0
624	68â€…Predicting 3-Year Mortality After PCI: Revised Clinical Syntax Model Based on Patient Level Data from 7 Contemporary Stent Trials. Heart, 2014, 100, A38.2-A39.	2.9	0
625	TCT-379 Independent and Combined Effect of Chronic Kidney Disease and Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents: Results from a Patient-Level Pooled Analysis of Randomized Controlled Trials. Journal of the American College of Cardiology, 2015, 66, B152.	2.8	0
626	TCT-425 Rotterdam Radial Access Research: Radial Artery Access Evaluation After Coronary Procedures With Very High Resolution Ultrasound; The Punctureâ€™s Footprint. Journal of the American College of Cardiology, 2015, 66, B173.	2.8	0
627	TCT-272 Everolimus-eluting stent versus bare-metal stent in diabetic patients with ST-segment elevation myocardial infarction. Insights from the EXAMINATION trial. Journal of the American College of Cardiology, 2015, 66, B107.	2.8	0
628	11â€…Predicting the outcome of reperfusion acutely in patients with STEMI â€“ derivation and validation of the ATI score. Heart, 2016, 102, A6.2-A6.	2.9	0
629	TCT-475 Effect of Stent Diameter in Women Undergoing Percutaneous Coronary Intervention with Early- and New-Generation Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. Journal of the American College of Cardiology, 2016, 68, B191.	2.8	0
630	Bivalirudin Versus Unfractionated Heparin for Acute Coronary Syndromes: Do We Have a Winner?. Revista Espanola De Cardiologia (English Ed), 2016, 69, 721-724.	0.6	0

#	Article	IF	Citations
631	Bivalirudina frente a heparina no fraccionada en sÃndromes coronarios agudos: Â¿hay un vencedor?. Revista Espanola De Cardiologia, 2016, 69, 721-724.	1.2	0
632	Response by Costa et al to Letter Regarding Article, â€œThe Rotterdam Radial Access Research: Ultrasound-Based Radial Artery Evaluation for Diagnostic and Therapeutic Coronary Proceduresâ€. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	0
633	Bivalirudin in Acute Coronary Syndromes. New England Journal of Medicine, 2016, 374, 284-286.	27.0	0
634	Response by Valgimigli and Gargiulo to Letter Regarding Article, â€œA Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?â€. Circulation, 2017, 135, e1037-e1038.	1.6	0
635	Expanded clinical use of everolimus eluting bioresorbable vascular scaffolds for treatment of coronary artery disease. Catheterization and Cardiovascular Interventions, 2017, 90, 58-69.	1.7	0
636	Stent and Dual Antiplatelet Therapy Duration Comparisons in the Setting of a Multicenter Randomized Controlled Trial: Can the Operator Experience Affect the Study Results?. Journal of the American Heart Association, 2017, 6, .	3.7	0
637	Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry. Thrombosis and Haemostasis, 2018, 118, 852-863.	3.4	0
638	â€˜Ten Commandmentsâ€™ of the 2017 ESC DAPT focused update Guidelines. European Heart Journal, 2018, 39, 186-186.	2.2	0
639	Real-world application of currently available decision models for dual antiplatelet therapy duration in acute coronary syndrome. Journal of Cardiovascular Medicine, 2018, 19, 310-313.	1.5	0
640	TCT-170 Impact of rate of recruitment on all-cause mortality: Insights from the GLOBAL LEADERS all-comers trial. Journal of the American College of Cardiology, 2018, 72, B72-B73.	2.8	0
641	TCT-112 Patient-oriented clinical outcomes and net adverse cardiovascular event in the Global Leaders trial. Journal of the American College of Cardiology, 2018, 72, B49.	2.8	0
642	Reply. JACC: Cardiovascular Interventions, 2018, 11, 1785-1786.	2.9	0
643	The MATRIX trial â€“ Author's reply. Lancet, The, 2019, 393, 1803-1804.	13.7	0
644	Complete revascularisation in STEMI: consider the benefits but do not forget the risks!. Annals of Translational Medicine, 2019, 7, S331-S331.	1.7	0
645	The benefit and harm of treating STEMI: Between ischemia, bleeding, and reperfusion injury. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 259-261.	1.0	0
646	Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents for Primary PCI. JACC: Cardiovascular Interventions, 2020, 13, 2314-2316.	2.9	0
647	Long-Term Risk of Major Adverse Cardiovascular Events in Patients With Acute Coronary Syndrome: Prognostic Role of Complete Blood Cell Count. Angiology, 2020, 71, 831-839.	1.8	0
648	Antithrombotic therapy in heart failure and sinus rhythm: the ongoing search for a better match of patients to therapy. European Journal of Heart Failure, 2021, 23, 657-660.	7.1	0

#	Article	IF	Citations
649	No free lunchâ€"the price of double versus triple antithrombotic therapy in patients with atrial fibrillation after ACS or PCI. Annals of Translational Medicine, 2020, 8, 516-516.	1.7	0
650	Antithrombotic treatment strategies after PCI â€“ Authors' reply. Lancet, The, 2020, 395, 867-868.	13.7	0
651	Competing risks in the duration of dual antiplatelet therapyâ€"the case for shorter treatment. , 2021, , 111-130.		0
652	Response by Gargiulo et al to Letter Regarding Article, â€œCangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segmentâ€"Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trialâ€: Circulation, 2021, 143, e797-e798.	1.6	0
653	Intimal Flap Sealing and Healing of Spontaneous Coronary Artery Dissection With Drug-Eluting Balloons. JACC: Cardiovascular Interventions, 2021, 14, 1843-1845.	2.9	0
654	Selatogrel and other P2Y12 inhibitorsâ€™ putative off-target effects. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	1.9	0
655	Atrial Interventions. , 2022, , 309-337.		0
656	AMI on the move. EuroIntervention, 2011, 7, 415-419.	3.2	0
657	Abstract 12930: Neutrophil Extracellular Traps Correlate With Impaired Myocardial Reperfusion in Patients With St Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention. Circulation, 2014, 130, .	1.6	0
658	Radial and Femoral Access in Percutaneous Intervention. , 2015, , 361-371.		0
659	Atrial Fibrillation on Non-vitamin K Antagonist Oral Anticoagulant Undergoing Elective Percutaneous Coronary Intervention for Stable Effort Angina. , 2017, , 19-38.		0
660	Trans-radial and Trans-femoral Intervention. , 2017, , 9-15.		0
661	Will PIONEER AF-PCI change my practice?. EuroIntervention, 2017, 13, e609-e612.	3.2	0
662	Transradial left main PCI is safe and effective. EuroIntervention, 2018, 14, 1073-1075.	3.2	0
663	Association of Serum PCSK9 with Near-Infrared Spectroscopy Derived Lipid Core Burden Index and Long-Term Cardiac Outcome. SSRN Electronic Journal, 0, , .	0.4	0
664	The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events?. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e29-e30.	3.0	0
665	Therapeutic Considerations with Revascularization in Chronic Kidney Disease: Radial Versus Femoral Arterial Access. , 2020, , 85-101.		0
666	The Effects of Cangrelor on Platelet Aggregation in STEMI Patients. JACC: Cardiovascular Interventions, 2022, 15, 229-230.	2.9	0

#	Article	IF	Citations
667	Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens. Journal of Thrombosis and Thrombolysis, 2022, , 1.	2.1	0